Arcutis Biotherapeutics Inc (NASDAQ: ARQT) on Tuesday, soared 7.72% from the previous trading day, before settling in for the closing price of $14.38. Within the past 52 weeks, ARQT’s price has moved between $6.99 and $16.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 349.37% over the past five years. The company achieved an average annual earnings per share of 50.00%. With a float of $104.14 million, this company’s outstanding shares have now reached $117.85 million.
Let’s look at the performance matrix of the company that is accounted for 342 employees. In terms of profitability, gross margin is 90.27%, operating margin of -65.33%, and the pretax margin is -70.92%.
Arcutis Biotherapeutics Inc (ARQT) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arcutis Biotherapeutics Inc is 12.22%, while institutional ownership is 101.79%. The most recent insider transaction that took place on Mar 03 ’25, was worth 36,735. In this transaction an insider of this company sold 2,819 shares at a rate of $13.03, taking the stock ownership to the 167,043 shares. Before that another transaction happened on Mar 04 ’25, when Company’s insider sold 954 for $13.28, making the entire transaction worth $12,673. This insider now owns 166,089 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 50.00% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Arcutis Biotherapeutics Inc (ARQT) is currently performing well based on its current performance indicators. A quick ratio of 3.97 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.16, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach 0.30 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) saw its 5-day average volume 2.18 million, a negative change from its year-to-date volume of 2.23 million. As of the previous 9 days, the stock’s Stochastic %D was 87.70%. Additionally, its Average True Range was 1.09.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 91.31%, which indicates a significant decrease from 99.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.05% in the past 14 days, which was higher than the 74.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.54, while its 200-day Moving Average is $10.87. Nevertheless, the first resistance level for the watch stands at $15.94 in the near term. At $16.39, the stock is likely to face the second major resistance level. The third major resistance level sits at $17.28. If the price goes on to break the first support level at $14.60, it is likely to go to the next support level at $13.71. The third support level lies at $13.26 if the price breaches the second support level.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
Market capitalization of the company is 1.84 billion based on 118,638K outstanding shares. Right now, sales total 196,540 K and income totals -140,040 K. The company made 71,360 K in profit during its latest quarter, and -10,790 K in sales during its previous quarter.
